Astellas Drug Acquired in $5.9B Deal Wins FDA Approval in Vision-Loss Disorder
MedCity News
AUGUST 7, 2023
The regulatory decision comes as safety concerns emerge around the first therapy for the disease, an Apellis Pharmaceuticals product. Izervay, a drug developed by Astellas Pharma subsidiary Iveric Bio, is now the second approved therapy for the degenerative vision-loss disorder geographic atrophy.
75 
Let's personalize your content